Carcinogenesis and Chemoprevention

致癌与化学预防

基本信息

批准号：
10333246
负责人：
Frank G. Ondrey
金额：
$ 4.85万
依托单位：
UNIVERSITY OF MINNESOTA
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
起止时间：
1998-06-01 至 2024-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10333246
关键词：
Address Agriculture Analytical Biochemistry Area Award Basic Science Biochemical Pathway Biological Markers Biological Sciences Biometry Budgets Cancer Burden Cancer Center Cancer Center Support Grant Carcinogen exposure Carcinogenesis Mechanism Catchment Area Categories Chemicals Chemoprevention Chest Clinical Chemoprevention Clinical Research Clinical Trials Clinical Trials Network Collaborations Comparative Pathology Cutaneous Data Development Direct Costs Doctor of Philosophy Eligibility Determination Engineering Environment Environmental Health Evolution Faculty Family Flow Cytometry Shared Resource Focus Groups Food Funding Future Ginger Goals Group Meetings Growth Head and Neck Surgeon Head and neck structure Healthcare Human Individual Institutes Institution Intervention Knowledge Lead Leadership Malignant Neoplasms Medicine Minnesota Minority Groups Molecular National Cancer Institute Natural Resources Organ Otolaryngologist Otolaryngology Paper Patients Peer Review Pharmacy facility Pilot Projects Population Populations at Risk Prevention strategy Prostate Public Health Public Health Schools Public Policy Publications Publishing Request for Proposals Research Research Personnel Research Project Grants Research Support Resource Sharing Resources Risk Running Schools Science Scientist Screening for cancer Shapes Site Smoker Source Strategic Planning Structure Techniques Tobacco Tobacco use Tobacco-Related Carcinoma Translating Translations United States National Institutes of Health Universities Veterinary Medicine Work base burden of illness cancer biomarkers cancer chemoprevention cancer clinical trial cancer genomics cancer prevention cancer risk carcinogenesis chemical carcinogenesis cohort college dietary epidemiology study experience medical schools meetings member mid-career faculty novel personalized medicine pre-clinical preclinical study prevent professor programs recruit risk stratification smoking cessation specific biomarkers synergism tobacco regulation urologic working group

项目摘要

Carcinogenesis and Chemoprevention Program Summary The scientific goals of the Carcinogenesis and Chemoprevention Program are to identify biomarkers for tobacco-related cancer risk; and to understand how environmental and dietary chemicals contribute to carcinogenesis through specific biochemical pathways and to apply this knowledge for individualized cancer risk stratification and cancer prevention. The ultimate objective is to translate these findings into investigator- initiated clinical trials that change public policy and health care. To achieve our goals, we have successful, mature research programs which address the following aims: 1) to characterize the harmful effects of tobacco chemicals and products and develop biomarkers for cancer risk stratification in clinical and epidemiological studies; 2) to understand how chemicals in food and medicine and specific biochemical pathways may contribute to carcinogenesis; 3) to identify food products, as well as natural and synthetic chemicals, that reduce cancer risk. Drs. Lisa Peterson and Frank Ondrey lead the Program, which has 24 members, representing 14 departments and 8 schools or colleges (College of Biological Sciences; College of Food, Agriculture and Natural Resources; College of Pharmacy; College of Science and Engineering; College of Veterinary Medicine; Hormel Institute; Medical School, and School of Public Health). In the last budget year, these members were supported by $5.6 million in direct costs from the National Cancer Institute; funding from all peer-reviewed sources totaled $8.2 million in direct costs. Since 2013, Program members have published 628 papers, 20% of which resulted from intraprogrammatic collaborations, 20% from interprogrammatic collaborations, and 87% from external collaborations. Since 2013, 53 clinical trials in all clinical research categories have opened under this programmatic area and have accrued 7728 subjects. The Masonic Cancer Center (MCC) has provided substantial value to the program, including access to shared resources, recruiting 3 new faculty, funding of 10 pilot projects ($382,500 awarded), 1 research retreat, 1 strategic planning meeting, 24 meetings on recent Program member research projects, 2 special seminars, and 2 meetings to discuss specific requests for proposals from the NIH. A monthly interprogrammatic translational biomarker focus group brings together population scientists and clinicians with basic research groups developing specific biomarkers. The Program's future direction fits well within the MCC's strategic plan. We will continue the translation of our basic research into chemoprevention clinical trials (Scientific Priority for Growth 3- SPG3). We are actively using biomarkers to understand carcinogenesis and to develop strategies to personalize cancer screening and treatments (SPG4). Program members are actively involved in the planning of the 10,000 Family cohort (SPG5), and this resource will be invaluable for the translation of our science to the catchment area. Lastly, we plan to use tobacco-related biomarkers to develop individually targeted smoking cessation and screening protocols in Minnesota's minority populations who have a disproportionate cancer burden (SPG6).

致癌和化学预防计划摘要致癌和化学预防计划的科学目标是确定癌症发生的生物标志物与烟草相关的癌症风险；并了解环境和膳食化学物质如何促进通过特定的生化途径致癌，并将这些知识应用于个体化癌症风险分层和癌症预防。最终目标是将这些发现转化为研究者- 发起了改变公共政策和医疗保健的临床试验。为了实现我们的目标，我们取得了成功，成熟的研究计划，旨在实现以下目标：1）描述烟草的有害影响化学品和产品，并开发临床和流行病学癌症风险分层的生物标志物研究； 2) 了解食品和药品中的化学物质以及特定的生化途径如何促进致癌作用； 3) 识别食品以及天然和合成化学品，降低癌症风险。博士。 Lisa Peterson 和 Frank Ondrey 领导该计划，该计划有 24 名成员，代表14个系和8个学院（生物科学学院、食品学院、农业和自然资源；药学院；科学与工程学院；学院兽医学；荷美尔研究所；医学院和公共卫生学院）。在上一个预算年度，这些成员得到国家癌症研究所 560 万美元的直接费用支持；资金来自所有经过同行评审的来源的直接成本总计为 820 万美元。自 2013 年以来，计划成员已发布 628 篇论文，其中 20% 来自项目内合作，20% 来自项目间合作合作，87%来自外部合作。自2013年以来，所有临床研究中有53项临床试验该计划领域已开设类别，已累计 7728 个科目。共济会癌症中心 (MCC) 为该计划提供了巨大的价值，包括访问共享资源、招聘 3 名新教师、资助 10 个试点项目（授予 382,500 美元）、1 次研究务虚会、1 次战略规划会议、 24次关于近期计划成员研究项目的会议、2次专题研讨会和2次讨论会议向 NIH 提出具体的提案请求。每月一次的程序间转化生物标志物焦点小组将人口科学家和临床医生与开发特定生物标志物的基础研究小组聚集在一起。该计划的未来方向与中冶集团的战略规划非常契合。我们将继续翻译我们的化学预防临床试验的基础研究（科学增长优先 3- SPG3）。我们正在积极使用生物标志物来了解致癌作用并制定个性化癌症筛查和治疗的策略治疗（SPG4）。计划成员积极参与 10,000 名家庭队列的规划（SPG5），这一资源对于将我们的科学转化为流域地区来说将是非常宝贵的。最后，我们计划使用与烟草相关的生物标志物来开发单独有针对性的戒烟和筛查明尼苏达州癌症负担过重的少数族裔的方案 (SPG6)。